Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer

Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial

(2019) Bertrand Tombal et al.   LANCET ONCOLOGY

Enzalutamida y apalutamida en el tratamiento del cáncer de próstata no metastásico resistente a la castración: comparación indirecta de la eficacia

(2019) P. Nieto-Gómez et al.   Actas Urologicas Espanolas

MP52-19 IMPACT OF ENZALUTAMIDE ON PAIN AND HEALTH-RELATED QUALITY OF LIFE IN MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: PROSPER STUDY RESULTS

(2018) Fred Saad et al.   JOURNAL OF UROLOGY

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

(2018) Maha Hussain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

(2018) Matthew R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer

(2018) Gabriel Tremblay et al.   Cancer Management and Research

Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial

(2018) Fred Saad et al.   LANCET ONCOLOGY

Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostate

(2018) F. Rozet et al.   PROGRES EN UROLOGIE

Targeting bone metastases in prostate cancer: improving clinical outcome

(2015) Jean-Jacques Body et al.   Nature Reviews Urology

Simulation and Matching-Based Approaches for Indirect Comparison of Treatments

(2015) K. Jack Ishak et al.   PHARMACOECONOMICS

Overcoming barriers to the implementation of patient-reported outcomes in cancer clinical trials: the PROMOTION Registry

(2014) Fabio Efficace et al.   Health and Quality of Life Outcomes

Managing bone metastases and reducing skeletal related events in prostate cancer

(2014) Benjamin A. Gartrell et al.   Nature Reviews Clinical Oncology

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

(2014) Tomasz M. Beer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Health-related quality of life in prostate cancer

(2013) Saku Torvinen et al.   ACTA ONCOLOGICA

Evidence Synthesis for Decision Making 2

(2012) Sofia Dias et al.   MEDICAL DECISION MAKING

Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research

(2012) James E. Signorovitch et al.   VALUE IN HEALTH

Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1

(2011) Jeroen P. Jansen et al.   VALUE IN HEALTH

Comparative Effectiveness Without Head-to-Head Trials

(2010) James E. Signorovitch et al.   PHARMACOECONOMICS

Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy—Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer

(2008) David Cella et al.   VALUE IN HEALTH